BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21363886)

  • 21. A comparison of budesonide and mesalamine for active Crohn's disease.
    Lowry PW; Sandborn WJ
    Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
    [No Abstract]   [Full Text] [Related]  

  • 22. 6-Mercaptopurine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.
    Hayee BH; Harris AW
    Gastroenterology; 2005 Jan; 128(1):249; author reply 249-51. PubMed ID: 15633158
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS; Zlatanic J; Korelitz BI; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts.
    Peyrin-Biroulet L; Oussalah A; Roblin X; Sparrow MP
    Aliment Pharmacol Ther; 2011 Mar; 33(6):707-13. PubMed ID: 21251032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New research results give hope. Causal therapy of Crohn disease in sight].
    MMW Fortschr Med; 2004 Apr; 146(14):42-3. PubMed ID: 15344754
    [No Abstract]   [Full Text] [Related]  

  • 26. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease.
    Herfarth H; Tjaden C; Lukas M; Obermeier F; Dilger K; Müller R; Schölmerich J;
    Gut; 2006 Oct; 55(10):1525-6. PubMed ID: 16966711
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of chronic inflammatory bowel diseases].
    Beglinger C
    Ther Umsch; 1997 Nov; 54(11):649-53. PubMed ID: 9454368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Postoperative recurrence in Crohn's disease. Risk factors and methods of prevention].
    Karoui S; Kallel L; Boubaker J; Filali A
    Tunis Med; 2006 Oct; 84(10):595-8. PubMed ID: 17193847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study].
    Domènech E; Scala L; Bernal I; García-Planella E; Casalots A; Piñol M; Esteve-Comas M; Cabré E; Boix J; Gassull MA
    Gastroenterol Hepatol; 2004 Dec; 27(10):563-7. PubMed ID: 15574279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab for postsurgical endoscopic recurrence of Crohn's disease: no trumpets yet.
    Sorrentino D; Paviotti A
    Inflamm Bowel Dis; 2009 Oct; 15(10):1458-9. PubMed ID: 19462431
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.
    Bodini G; Giannini EG; De Maria C; Dulbecco P; Furnari M; Marabotto E; Savarino V; Savarino E
    Dig Liver Dis; 2017 Feb; 49(2):175-180. PubMed ID: 27864028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of postoperative Crohn's disease.
    Froehlich F; Juillerat P; Felley C; Mottet C; Vader JP; Burnand B; Michetti P; Gonvers JJ
    Digestion; 2005; 71(1):49-53. PubMed ID: 15711050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of postoperative recurrence of Crohn's disease.
    van Loo ES; Dijkstra G; Ploeg RJ; Nieuwenhuijs VB
    J Crohns Colitis; 2012 Jul; 6(6):637-46. PubMed ID: 22398096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevention of postoperative recurrence in Crohn's disease.
    Terdiman JP
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):616-20. PubMed ID: 17967564
    [No Abstract]   [Full Text] [Related]  

  • 36. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Angioedema in Crohn's disease possibly due to mesalazine].
    Nguyen-Khac E; Le Baron F; Thevenot T; Tiry-Lescut C; Tiry F
    Gastroenterol Clin Biol; 2002 May; 26(5):535-6. PubMed ID: 12122371
    [No Abstract]   [Full Text] [Related]  

  • 38. [From research to clinic: The case of Crohn's disease and Tumor Necrosis Factor].
    Pellicano R
    Minerva Gastroenterol Dietol; 2000 Jun; 46(2):131-8. PubMed ID: 19320082
    [No Abstract]   [Full Text] [Related]  

  • 39. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.